Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K

被引：15
|
作者：
Barrett, DG
Catalano, JG
Deaton, DN [1 ]
Long, ST
Miller, LR
Tavares, FX
Wells-Knecht, KJ
Wright, LL
Zhou, HQQ
机构：
[1] GlaxoSmithKline, Dept Med Chem, Res Triangle Pk, NC 27709 USA
[2] GlaxoSmithKline, Discovery Res Biol, Res Triangle Pk, NC 27709 USA
[3] GlaxoSmithKline, Dept Res Bioanal & Drug Metab, Res Triangle Pk, NC 27709 USA
[4] GlaxoSmithKline, Dept Mol Pharmacol, Res Triangle Pk, NC 27709 USA
[5] GlaxoSmithKline, Dept World Wide Phys Properties, Res Triangle Pk, NC 27709 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 10期
关键词：
cathepsin K; ketoamide; cysteine protease inhibitors;
D O I：
10.1016/j.bmcl.2004.02.085
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
An orally available series of ketoamide-based inhibitors of cathepsin K has been identified. Starting from a potent inhibitor with poor oral bioavailability, modifications to P-1 and P-1' elements led to enhancements in solubility and permeability. These improvements resulted in orally available cathepsin K inhibitors. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2543 / 2546
页数：4
相关论文
共 50 条
  • [21] Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen
    Mallinger, Aurelie
    Crumpler, Simon
    Pichowicz, Mark
    Waalboer, Dennis
    Stubbs, Mark
    Adeniji-Popoola, Olajumoke
    Wood, Bozena
    Smith, Elizabeth
    Thai, Ching
    Henley, Alan T.
    Georgi, Katrin
    Court, William
    Hobbs, Steve
    Box, Gary
    Ortiz-Ruiz, Maria-Jesus
    Valenti, Melanie
    Brandon, Alexis De Haven
    TePoele, Robert
    Leuthner, Birgitta
    Workman, Paul
    Aherne, Wynne
    Poeschke, Oliver
    Dale, Trevor
    Wienke, Dirk
    Esdar, Christina
    Rohdich, Felix
    Raynaud, Florence
    Clarke, Paul A.
    Eccles, Suzanne A.
    Stieber, Frank
    Schiemann, Kai
    Blagg, Julian
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1717 - 1735
  • [22] Discovery of potent, selective, orally bioavailable small molecule thrombin inhibitors using oxyguanidines as guanidine mimetics.
    Lu, TB
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U6 - U6
  • [23] Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin receptor
    Narayanan, Sanju
    Dai, Donghua
    Devambatla, Ravi Kumar Vyas
    Albert, Vincent
    Bruneau-Latour, Nicolas
    Vasukuttan, Vineetha
    Ciblat, Stephane
    Rehder, Kenneth
    Runyon, Scott P.
    Maitra, Rangan
    BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 66
  • [24] Characterization of an Orally Bioavailable, Small Molecule That Lowers Mutant Huntingtin Levels
    Sivasankaran, Rajeev
    Gubser-Keller, Caroline
    Shin, Youngah
    Monteys, Alejandro
    Beibel, Martin
    Renaud, Nicole
    Cha, Jang-Ho
    Davidson, Bev
    Borowsky, Beth
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 41 - 41
  • [25] Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Inhibitors of CDK8 for the Treatment of Cancer
    Li, Yangguang
    Liu, Yingtao
    Wu, Jianping
    Liu, Xiaosong
    Wang, Lin
    Wang, Ju
    Yu, Jiaojiao
    Qi, Hongyun
    Qin, Luoheng
    Ding, Xiao
    Ren, Feng
    Zhavoronkov, Alex
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (08) : 5439 - 5452
  • [26] Progress towards orally bioavailable, potent, and selective small-molecule inhibitors of CD73 for immunooncology
    Thomas-Tran, Rhiannon
    Lindsey, Erick
    Lawson, Kenneth
    Beatty, Joel
    Jeffrey, Jenna
    Fournier, Jeremy
    Mandal, Debashis
    Yan, Xuelei
    Drew, Samuel
    Walker, Nigel
    Moschuetz, Susanne
    Straeter, Norbert
    Chen, Ada
    Leleti, Manmohan Reddy
    Powers, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [27] The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K
    Mons, Elma
    Jansen, Ineke D. C.
    Loboda, Jure
    van Doodewaerd, Bjorn R.
    Hermans, Jill
    Verdoes, Martijn
    van Boeckel, Constant A. A.
    van Veelen, Peter A.
    Turk, Boris
    Turk, Dusan
    Ovaa, Huib
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2019, 141 (08) : 3507 - 3514
  • [28] MEDI 370-Evolution of selective, potent, and orally bioavailable small molecule Tie-2 kinase inhibitors
    Olivieri, Philip R., II
    Geuns-Meyer, Stephanie D.
    Hughes, Paul E.
    Albrecht, Brian K.
    Bellon, Steve
    Bready, James
    Caenepeel, Sean
    Cee, Victor J.
    Chaffee, Stuart C.
    Coxon, Angela
    Emery, Maurice
    Fretland, Jenne
    Gallant, Paul
    Gu, Yan
    Hodous, Brian L.
    Hoffman, Doug
    Johnson, Rebecca E.
    Kendall, Richard
    Kim, Joseph L.
    Long, Alexander M.
    Morrison, Michael
    Patel, Vinod F.
    Polverino, Anthony
    Rose, Paul
    Tempest, Paul
    Wang, Ling
    Whittington, Douglas A.
    Zhao, Huilin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 234
  • [29] Progress towards orally bioavailable, potent, and selective small-molecule inhibitors of CD73 for cancer immunotherapy
    Lindsey, E.
    Lawson, K.
    Thomas-Tran, R.
    Beatty, J.
    Fournier, J.
    Mandal, D.
    Yan, X.
    Drew, S.
    Jeffrey, J.
    Walker, N.
    Straeter, N.
    Moschuetz, S.
    Chen, A.
    Tan, J.
    Jin, L.
    Walters, M.
    Young, S.
    Schindler, U.
    Leleti, M.
    Powers, J.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E93 - E93
  • [30] An orally-bioavailable cathepsin K antagonist with anti-resorptive activity in vivo.
    Kimmel, DB
    Pennypacker, B
    Rodan, SB
    Wesolowski, G
    Duong, LT
    Venkatraman, S
    Setti, E
    Tian, ZQ
    Palmer, J
    Oballa, RM
    Robichaud, J
    Prasit, P
    Falueyret, JP
    Riendeau, D
    Percival, MD
    Rodan, GA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S166 - S166
12345